Eli Lilly Suit Over ‘Personalized’ Obesity Drugs Gets Go-Ahead

A federal judge allowed Eli Lilly & Co.‘s lawsuit alleging a drug compounder sold untested and unapproved versions of its obesity treatment to proceed while he also dismissed some of the drugmaker’s claims.

The company’s claim that Henry Meds unlawfully marketed and sold tirzepatide—Lilly’s diabetes and obesity treatment branded as Mounjaro and Zepbound—by advertising copycat versions as “patient-specific” can move forward, Judge Jon S. Tigar for the US District Court for the Northern District of California said in an order filed Wednesday.

“Since Lilly has adequately alleged that the claims of personalization are literally false, the Court presumes actual ...